1. Miyasaka Y., Barnes M.E., Gersh B.J. et al. Secular trends in incidence of atrial fibrillations in Olmsted Country, Minnecota, 19802000, and implications on the projections on future prevalence. Circulation 2006; 114: 119-125.
2. Stewart S., Hart C., Hole D., McMurray J. A population-based study of the long-term risk associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113 (5): 359-364.
3. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016; 50 (5): e1-e88.
4. Goette A., Schon N., Kirchhof P. et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012; 5: 43-51.
5. Yusuf S., Healey J.S., Pogue J. et al. Active I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364: 928-938.
6. Rimoldi S.F., Franz H., Messerli F.H. et al. Resistant hypertension: what the cardiologist needs to know. Eur Heart J 2015; 36 (40): 2686-2695.
7. Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51 (6): 1403-1419.
8. Sievert H., Schofer J., Ormiston J.A. et al. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention 2015; 10: 1213-1220.
9. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917.
10. Symplicity HTN-2 Investigators, Esler M.D., Krum H., Sobotka P.A. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
11. Bhatt D.L., Kandzari D.E., O'Neill W.W. et al.; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
12. Pathak A., Ewen S., Fajadet J. et al. From SYMPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go? EuroIntervention 2014; 10: 21-23.
13. Luscher T.F., Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? Eur Heart J 2014; 35: 1706-1711.
14. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-1357.
15. Hering D., Mahfoud F., Walton A.S. et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23 (7): 1250-1257.
Послать статью по эл. почте 
Оставить комментарий 
